Type 1 diabetes intervention trials

Pediatric Diabetes

Volumn 2, Issue 1, 2001, Pages 2-11

  Pietropaolo, Massimo ^a   Becker, Dorothy J ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Intervention trials; Islet cell autoimmunity; Prediction and prevention of type 1 diabetes; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; C PEPTIDE; CYCLOSPORIN A; GLUTAMATE DECARBOXYLASE; HLA DQ ANTIGEN; HLA DR ANTIGEN; INSULIN; MILK PROTEIN; NICOTINAMIDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIVER TOXICITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; RELATIVE; RISK; RISK BENEFIT ANALYSIS; SAMPLING; SCREENING TEST;

EID: 0035028347     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-543x.2001.00000.x-i2     Document Type: Article

References (78)

1. The NOD mouse
2. The NOD mouse model of type 1 diabetes: As good as it gets?
3. Spontaneous diabetes in gnotobiotic BB/W rat
4. Spontaneous autoimmune diabetes mellitus in the BB rat
5. IDDM prevention trials in progress - A critical assessment
6. Aspects of the etiology, prediction, and prevention of insulin-dependent diabetes mellitus in childhood
7. Preservation of β cell function in type 1 diabetes
8. Patient and family reflections on the use of subcutaneous insulin to prevent diabetes: A retrospective evaluation from a pilot prevention trial
9. Prevention of type 1 diabetes
10. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus. Diabetes control complications trial
11. Intensive diabetes therapy in childhood: Is it achievable? Is it desirable? Is it safe?
12. Therapeutic controversy. Prevention and treatment of diabetes in Children
13. Emergence of diabetes associated autoantibodies in the nutritional prevention of IDDM (TRIGR) project
14. Type I diabetes mellitus: A chronic autoimmune disease
15. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition
16. Immunobiology of autoimmunity
17. Immunologic diagnosis of autoimmuity
18. Molecular targets of the autoimmunity of type I diabetes
19. Use of recombinant proteins in the diagnosis of autoimmune connective tissue diseases
20. A novel radiobinding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM
21. ICA512 autoantibody radioassay
22. Highly sensitive assays of autoantibodies to thyroglobulin and thyroid peroxidase
23. Incidence of insulin dependent diabetes in England: A study in the Oxford region, 1985-6
24. Testing the linear destruction hyposthesis in type I diabetes: The Joslin study
25. Incidence of insulin-dependent diabetes mellitus in Colorado
26. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) registries: The descriptive epidemiology of racial differences
27. Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies
28. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes
29. Perspectives in diabetes. How, when, and why to predict IDDM
30. Perspectives in diabetes. Can we really predict IDDM?
31. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2β predict immune-mediated (Type 1) diabetes in relatives
32. Risk factors for insulin-dependent diabetes
33. Prevalence and incidence of insulin-dependent diabetes
34. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men. A nested case-control study
35. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives
36. Prediction of type I diabetes mellitus in first degree relatives using a combination of insulin, glutamic acid decarboxylase and ICA512bdc/IA-2 autoantibodies
37. Combined analysis of GAD65 and ICA512 (IA-2) autoantibodies in organ and non-organ specific autoimmune diseases confers high specificity for insulin-dependent diabetes mellitus
38. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes. The 2-year analysis of the German BABYDIAB study
39. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies can replace the histochemical islet cell antibody test
40. Prediction of insulin-dependint diabetes mellitus in siblings of children with diabetes
41. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
42. Risk factors for non-insulin dependent diabetes
43. The cardiovascular health study: Design and rationale
44. Evidence of islet cell autoimmunity in elderly patients with Type 2 diabetes mellitus
45. Clinical trials of Cyclosporin in IDDM
46. Factors associated with early remission of Type I diabetes in children treated with cyclosporine
47. Cyclosporine and azathioprine for IDDM
48. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks
49. Immunotherapy for Type I Diabetes
50. Is it the time to draw the curtain on immune intervention trials in newly diagnosed patients with IDDM?
51. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients
52. Immunosuppression with azathioprine and prednisone in recent- onset insulin-dependent diabetes mellitus
53. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine
54. The potential role of nicotinamide in the secondary prevention of IDDM
55. A population based strategy to prevent insulin-dependent diabetes using nicotinamide
56. An attempt to prevent Type 1 diabetes
57. The Diabetes Prevention Trial-type 1 diabetes (DPT-1): Implementation of screening and staging of relatives
58. Multiple beta cells antibodies are not associated with high risk HLA genotypes in schoolchildren from the general population
59. Are GAD65 and IA-2 autoantibodies sufficient to predict Type 1 diabetes?
60. Absence of islet autoantibodies at diabetes onset does not rule out Type 1A diabetes
61. T-cell responses to autoantigens in IDDM. The search for the holy grail
62. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients
63. Persistent T cell anergy in human type 1 diabetes
64. Genetic, autoimmune, and clinical characteristics of childhood- and adultonset Type 1 diabetes
65. Effect of intensive therapy on residual β-cell function in patients with Type 1 diabetes in the Diabetes Control and Complication Trial. A randomized, controlled trial
66. Relationship of β-cell function and autoantibodies to progression and nonprogression of subclinical Type 1 diabetes
67. Dual parameter linear model for prediction of onset of type I diabetes in islet cell antibody positive relatives
68. The appropriate use of B-cell function testing in the preclinical period of type I diabetes
69. The ICARUS Group. Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans
70. Dual-parameter model for prediction of type I diabetes mellitus
71. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus
72. Does C-peptide has a physiological role?
73. Proinsulin C-peptide-biological activity?
74. Differential effects of proinsulin C-peptide fragments on Na+, K+-ATPase activity in synergism with neuropeptide Y
75. Precipitation of IDDM by the ICA69 T cell epitope peptide, Tep69
76. Immunologic 'vaccination' for the prevention of autoimmune diabetes (Type 1A)
77. CD3 antibody-induced dominant self tolerance on overtly diabetic NOD mice